Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
Boston, MA
|
May 23, 2023 10:00 AM Eastern Daylight Time
Q-Vant Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced very positive results comparing Q-Vant's sustainable saponin-based adjuvant, Q-VET-S®, to Croda's Quil-A® adjuvant. These results were obtained through a collaborative study with Kansas State University, utilizing their subunit classic swine fever (CSF) vaccine.
The CSF vaccine was developed by Kansas State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the Center for Vaccine Evaluation, where he and his team are working on novel vaccine and diagnostic strategies aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF), and other emerging viral diseases of swine.
Juan Jose Albarran, the chief commercial officer of Q-Vant Biosciences, said, "The development of Q-VET-S® and its proven effect marks a major milestone in the field of vaccine adjuvants. Our cutting-edge technology not only ensures a reliable supply for the pharmaceutical sector but also addresses the environmental concerns associated with Quillaja Saponaria harvesting. By focusing on sustainability, we are playing a significant role in protecting Chile's forests while simultaneously advancing global animal and human health."
For more information about Q-Vant Biosciences and Q-VET-S, please visit www.q-vant.com.
About Kansas State University:
Kansas State University, established in 1863, is a leading public research university with a mission to foster excellent teaching, research, and service that develops a highly skilled and educated citizenry necessary to advancing the well-being of Kansas, the nation, and the international community. The university is committed to advancing knowledge through research and creative activities, developing leaders, and contributing to the global community's well-being.
About Q-VANT Biosciences
Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The companyâs next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 â enabling the production of billions of doses annually to meet todayâs increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com.
Contact Details
Q-Vant Biosciences
Doug Klaiber
Company Website
